Ignite Creation Date:
2024-05-05 @ 11:26 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00047554
Status:
TERMINATED
Last Update Posted:
2013-05-15
First Post:
2002-10-08
Brief Title:
Study of TRAVATAN in Subjects With Iris Pigmentation Changes
Sponsor:
Alcon Research
Organization:
Alcon Research
Study Overview
Official Title:
A Five-Year Multicenter Commercial Label Safety Study of TRAVATAN 0004 in Patients With TRAVATAN-Induced Iris Pigmentation Changes
Status:
TERMINATED
Status Verified Date:
2013-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Study objectives met
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study was to monitor iris pigmentation changes over a 5-year period in patients with open-angle glaucoma or ocular hypertension To be eligible for the study these individuals must have experienced an iris pigmentation change while previously dosing with TRAVATAN
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None